The Top 5 Biosimilar Articles for the Week of January 25

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of January 25, 2021.

Number 5: Charles Bennett, MD, PhD, a hematologist, oncologist, and professor at the University of South Carolina, explained the many sticking points that prevent biosimilar savings.

Number 4: It took Henlius years to get a rituximab biosimilar approved in China. Now, that process could be cut in half, owing to significant regulatory reforms.

Number 3: An attempt by investigators to understand whether regulatory and scientific sources are consistent with each other in their reporting of quality attributes for biosimilars has demonstrated general conformance between these 2 sources of biosimilar information.

Number 2: The CEO of Prestige Biopharma said that biosimilars will be the cornerstone for a leap into biologics development and commercialization. Meanwhile, Innovent Biologics reaches a marketing agreement.

Number 1: Coherus BioSciences CEO Dennis M. Lanfear discusses the company's biosimilar marketing prospects in 2021.

To read all of these articles and more, visit centerforbiosimilars.com.